CMS proposes updates to coverage policy for autologous blood-derived products for chronic non-healing wounds

Dec. 23, 2020

The Centers for Medicare & Medicaid Services (CMS) issued a proposal to cover autologous platelet-rich plasma (PRP) for the treatment of chronic non-healing diabetic wounds, according to a press release.

PRP is a blood-derived product prepared from the patient’s own blood to be used as a wound covering in the management of chronic wounds.

In addition, CMS proposed that coverage of autologous PRP for the treatment of all other chronic non-healing wounds will be determined by local Medicare Administrative Contractors (MACs).

The proposal would update the current payment policy in which PRP is only covered under the Coverage with Evidence Development (CED) pathway for the treatment of chronic, non-healing diabetic, venous, and pressure wounds when beneficiaries are enrolled in a clinical study. 

CMS is seeking public comment on the proposed decision memo.

 Visit CMS for more news

Photo 111134338 © Kwanchaidt | Dreamstime.com
Photo 81363766 © Andrii Kucher | Dreamstime.com
Photo 125378010 © Komgrit Pradissagul | Dreamstime.com
Photo 36810879 © Tyler Olson | Dreamstime.com